Remdesivir had saved many lives during the deadly second wave of COVID-19. Now, a new research has revealed that Remdesivir, when compared with the standard of
Ramping up production capacities and meeting supply demands of new COVID-19 vaccines and therapeutics is likely to be the key focus for pharma companies in 2022.
Ramping up production capacities and meeting supply demands of new COVID-19 vaccines and therapeutics is likely to be the key focus for pharma companies in 2022.